Cash-hungry Mabwell seeks financial tonic from Hong Kong investors
Despite already having three products on the market, unlike many of its Hong Kong-listed peers, the drug maker is struggling to cover its daily operational costs Key Takeaways: Mabwell said…
Recent Articles
RELATED ARTICLES
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK - Cancer drug maker Genfleet joins Hong Kong IPO influx
- Hong Kong gains clout as preferred IPO watering hole for Chinese companies
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Haitian looks for new financial flavor in Hong Kong IPO
603288.SHG
- Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
-
CATL leads new charge of Mainland-listed companies into Hong Kong
300750.SHE
